<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913118</url>
  </required_header>
  <id_info>
    <org_study_id>QF-CAP-20160402</org_study_id>
    <nct_id>NCT02913118</nct_id>
  </id_info>
  <brief_title>Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia</brief_title>
  <official_title>Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia: A Multicenter Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingfeng Pharmaceutical Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingfeng Pharmaceutical Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjunctive Therapy of AndrographolidSulfonate in Community Acquired Pneumonia: A Multicenter,
      Randomized,Double-blinded, Placebo Controlled Clinical Trial. The hypothesis is that
      combination therapy with Andrographolid Sulfonatein injection and antibacterial is
      significantly better than antibacterial alone in achieving clinical stability among
      hospitalized CAP patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to clinical stability</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of study participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>14 days</time_frame>
    <description>symptoms and signs, blood and urine routine, liver and kidney function monitoring, ECG, side effects of long-time using of antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the duration of fever</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the initial treatment failure rate</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in hospital</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire for hospitalization expenses</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration of intravenous antibiotic treatment</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of diarrhea and intestinal dysbacteriosis</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>standard antibiotic treatment +AS injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Andrographolid Sulfonate Injection (AS Injection) plus one of 3 antibiotics in China CAP Guideline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard antibiotic treatment + AS placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AS placebo (NS injection) plus one of 3 antibiotics in China CAP Guideline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Andrographolid Sulfonate Injection (AS Injection)</intervention_name>
    <arm_group_label>standard antibiotic treatment +AS injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalosporin</intervention_name>
    <arm_group_label>standard antibiotic treatment +AS injection</arm_group_label>
    <arm_group_label>standard antibiotic treatment + AS placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin, Minocycline or Doxycycline</intervention_name>
    <arm_group_label>standard antibiotic treatment +AS injection</arm_group_label>
    <arm_group_label>standard antibiotic treatment + AS placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-clavulantic acid</intervention_name>
    <arm_group_label>standard antibiotic treatment +AS injection</arm_group_label>
    <arm_group_label>standard antibiotic treatment + AS placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoroquinolones</intervention_name>
    <arm_group_label>standard antibiotic treatment +AS injection</arm_group_label>
    <arm_group_label>standard antibiotic treatment + AS placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>standard antibiotic treatment + AS placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18-75 years, no gender restrictions.

          -  Voluntary participation, all participants provide written informed consent.

          -  Volunteers are hospitalized patients

          -  Patients are hospitalized for community acquired pneumonia with T≥38°C within 24 hours
             before being enrolled Diagnosis of CAP(Chinese Guideline for Diagnosis and Management
             of Community Acquired Pneumonia in Adults 2016)

               1. Pneumonia that is acquired in community

               2. Symptoms and signs of pneumonia:

               1. Presence of cough, expectoration or exacerbation of chronic airways disease, with
                  or without purulent sputum/chest pain/dyspnea/hemoptysis.

               2. Presence offever.

               3. Lung consolidation and/or moist rales.

               4. Peripheral blood（WBC）&gt;10×109/L or &lt;4×109/L, with or without nuclear left shift;
                  3. Chest radiograph shows new ground-glass opacity, patchy infiltration,
                  consolidation or interstitial changes, with or without pleural effusion.

        Patients who meet 1,3 and any one item in 2, exclude one of the following are clinically
        classified as CAP: pulmonary tuberculosis, cancer, non-infectious interstitial lung
        disease, pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophilia and
        pulmonary vasculitis.

          -  CURB 65≥1 point,Each risk factor scores one point, for a maximum score of 5:

               -  Confusion of new onset

               -  Blood Urea nitrogen greater than 7 mmol/l (19 mg/dL)

               -  Respiratory rate of 30 breaths per minute or greater

               -  Blood pressure less than 90 mmHg systolic or diastolic blood pressure 60 mmHg or
                  less

               -  Age 65 or older

          -  Within 72 hours after symptom onset

        Exclusion Criteria:

          -  Known allergy to AS

          -  Pregnant or breast-feeding

          -  Heart dysfunction, NYHA III-IV class

          -  Hematological system diseases, such as lymphoma, leukemia, agranulocytosis (neutrophil
             count&lt; 0.5×109/L).

          -  Autoimmune diseases and disease active

          -  Terminal malignant tumor

          -  Long-term treatment of high dose corticosteroids (prednisone 10mg/d ≥2 weeks) or
             immunosuppressive agents

          -  Inflammatory bowel disease, such as Crohn's disease, ulcerative colitis

          -  Chronic renal failure, eGFR&lt;50 ml/min/1.73m2

          -  Severe liver function damage, ALT or AST greater than or equal to 2 times the upper
             limit of normal

          -  Hypernatremia, serum sodium≥145mmol/L

          -  Diagnosis as severe pneumonia:

        Diagnostic criteria of severe pneumonia: patients who meet one major criteria or at least 3
        of these minor criteria are classified as severe cases: Major criteria:①the need for
        invasive mechanical ventilation②sepsis shock after active fluid resuscitation still need
        vasoactive drugs; Minor criteria:①respiratory rate &gt;30 breaths/min,
        ②PaO2/FiO2≤250mmHg（1mmHg=0.133kPa）, ③multilobar infiltrates, ④confusion
        or/andunorientation, ⑤bloodurea nitrogen level≥20mg/dl（7.14mmol/L）, ⑥systolic pressure
        ＜90mmHg need active fluid resuscitation

          -  Defervescence by using corticosteroid after symptom onset.

          -  Patients who participated another intervention study within a month

          -  Other conditions not suitable for inclusion according to the investigator' judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bin Cao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Chen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Xing Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuguang Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Hospital of TCM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Gu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhenyang Xu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Luhe Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Yi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shufeng Xu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of QinHuangDao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Central Hospital of ZiBo City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Cao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The General Hospital of Tianjin Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuping Li, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Wenzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xuedong Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qingdao Municipal Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Fan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhigang Cai, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinri Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Shanxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Su, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Wang, Professor</last_name>
    <phone>+86 13901122992</phone>
    <email>cyh-birm@263.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bin Cao, Professor</last_name>
    <phone>+86 13911318339</phone>
    <email>caobin_ben@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojing Cui, MD</last_name>
      <phone>+86 10 84206269</phone>
      <email>cuixiaojing86@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Bin Cao, MD</last_name>
      <phone>+86 13911318339</phone>
      <email>caobin_ben@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital of TCM</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing LuHe Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fu Xing Hospital, Capital Medical Unviersity</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Chen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou University</name>
      <address>
        <city>Wenzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Hospital of QinHuangDao</name>
      <address>
        <city>QinHuangDao</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of NanChang University</name>
      <address>
        <city>NanChang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of ZiBo City</name>
      <address>
        <city>ZiBo</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

